Navigation Links
Brupbacher Prize goes to cancer researcher Michael Karin
Date:1/29/2013

Molecular biologist Michael Karin is to receive this year's Charles Rodolphe Brupbacher Prize for Cancer Research in recognition of his studies on the role of chronic inflammation in the development of tumors. The award, which carries CHF 100,000 in prize money, is considered one of the highest accolades for cancer researchers worldwide. The awards ceremony takes place in Zurich this Thursday in the framework of an international symposium on "Breakthroughs in Cancer Research and Therapy".

On Thursday, 31 January 2013, the Charles Rodolphe Brupbacher Prize will be awarded for the 11th time to a scientist for outstanding achievements in cancer research. This year's award goes to Michael Karin, professor in the Department of Pharmacology at the University of California in San Diego.

Michael Karin is one of the most cited authors in biomedical science. He made a name for himself with his fundamental studies on the role of chronic inflammation in tumor development, such as hepatic cancer following an infection with the hepatitis B or C viruses or stomach cancer through an infection with the gastric bacterium Helicobacter pylori. A specific viral or bacterial pathogen, however, is not necessary because any chronic inflammatory damage to the intestinal mucosa carries a significantly increased risk of colon cancer. This includes immunologically induced inflammatory bowel diseases.

Evidence of causal link between inflammation and carcinogenesis

Karin is an internationally renowned expert on signaling pathways, transduction pathways that enable cells to respond to external influences. Karin is particularly interested in the influence of stress and infections. He showed how the cell's normal signaling pathways can go awry in the event of chronic infections, with cancer as a possible consequence.

Michael Karin's work has greatly advanced our understanding of the molecular basis of tumour development and is of vital importance in devising new strategies for prevention and therapy.

Public lecture by Gottfried Schatz and prizes for young scientists

On the eve of the award ceremony, the Brupbacher Foundation is holding a public lecture by Professor Gottfried Schatz entitled "Die tragische Substanz. Wie genetische Fehler Alterung und Krebs bewirken". Schatz is emeritus professor of the University of Basel and a biochemist of international standing especially in the field of mitochondria, the energy-providing powerhouses in the cell.

The last item on the symposium's program is devoted to young scientists: Up to five junior researchers will receive a Young Investigator Award at the conclusion of the symposium on Friday morning.


'/>"/>

Contact: Paul Kleihues
office@brupbacher-foundation.org
41-797-383-472
University of Zurich
Source:Eurekalert

Related biology news :

1. Brandeis scientists win prestigious prize for circadian rhythms research
2. Stanford and MIT scientists win Perl-UNC Neuroscience prize
3. March of Dimes awards $250,000 prize to 2 scientists who pioneered advances in skin disorders
4. The Brain Prize 2012 is presented May 9th
5. UCSF pair win Gruber Foundation Neuroscience prize
6. Mason environmentalist awarded Blue Planet Prize for lifetime achievement in conservation
7. Reaxys announces winners of the 2012 Reaxys Ph.D. Prize
8. $500,000 Gruber Foundation Genetics Prize goes to Philadelphia scientist
9. Dr. Douglas Wallace to receive Gruber Foundation 2012 Genetics Prize
10. University of Tennessee professor wins worlds top prize for ecology, environmental science
11. World Food Prize winner among speakers at agronomy, crop and soil science societies meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... firm Parks Associates announced today that Tom Kerber , ... Meeting , October 11 in Scottsdale, Arizona . Kerber ... smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction ...
Breaking Biology Technology: